RETA - Reata Pharmaceuticals Stock Price, News & Analysis

$24.92 -0.13 (-0.52 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$25.05
Today's Range$24.52 - $25.64
52-Week Range$18.51 - $40.88
Volume154,077 shs
Average Volume119,720 shs
Market Capitalization$653.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals logoReata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:RETA
  • CUSIP: N/A
  • Web: reatapharma.com
Debt:
  • Debt-to-Equity Ratio: -0.15%
  • Current Ratio: 3.18%
  • Quick Ratio: 3.18%
Sales & Book Value:
  • Annual Sales: $49.86 million
  • Price / Sales: 13.05
  • Book Value: ($5.07) per share
  • Price / Book: -4.92
Profitability:
  • Trailing EPS: ($1.46)
  • Net Income: $-6,220,000.00
  • Net Margins: -69.44%
  • Return on Assets: -34.36%
Misc:
  • Employees: 75
  • Outstanding Shares: 26,110,000
 

Frequently Asked Questions for Reata Pharmaceuticals (NASDAQ:RETA)

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.11. The company had revenue of $12.60 million for the quarter, compared to analysts' expectations of $12.54 million. The firm's quarterly revenue was up .0% on a year-over-year basis. View Reata Pharmaceuticals' Earnings History.

Where is Reata Pharmaceuticals' stock going? Where will Reata Pharmaceuticals' stock price be in 2017?

8 Wall Street analysts have issued 12 month target prices for Reata Pharmaceuticals' shares. Their predictions range from $43.00 to $78.00. On average, they expect Reata Pharmaceuticals' stock price to reach $54.71 in the next year. View Analyst Ratings for Reata Pharmaceuticals.

What are Wall Street analysts saying about Reata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (11/16/2017)
  • 2. Cowen and Company analysts commented, "RETA reported 3Q17 financials yesterday, noting that the three major programs." (11/14/2017)
  • 3. Piper Jaffray Companies analysts commented, "We hosted Reata for investor meetings and came away with positive insights on its clinical progress in CTD-PAH, Friedreich's Ataxia, and other orphan disorders. On CTDPAH, we believe the CATALYST trial is progressing well and were reminded as to why we're confident in this capital-efficient trial design. In FA, we look forward to 'hypothesisgenerating' results in mid'17 which could demonstrate the first activity from omav' in a neurodegenerative condition ' potentially opening the door to a pivotal program in FA and/ or studies in other indications. To set up these results, we're hosting a KOL call on FA next Monday 4/3/17 ' contact your PJC rep for details. Overall, we expect Reata could conduct pivotal stage programs in 3+ orphan indications within the next 12 months, and continue to see this platform as under-valued compared to other multi-candidate, platform-enabled drug developers. In advance of clinical progress yet in 2017, we reiterate OW." (3/28/2017)
  • 4. Stifel Nicolaus analysts commented, "Our positive thesis centers on what we see as blockbuster potential for lead asset bardoxolone methyl (BARD) in chronic kidney disease (CKD) caused by Alport syndrome. Yes, it's true that investors previously abandoned BARD in CKD after the P3 BEACON trial was halted in 2012 due to serious adverse events ' but we and our KOL consultants believe the underlying causes behind the prior safety issues are now well characterized and understood - and importantly, are prospectively controlled for in ongoing clinical trials - and therefore unlikely to re-emerge. Strong BARD efficacy across multiple prior CKD trials makes us confident that the drug will work as expected when initial P2 data are announced in 2H17. We are also sanguine on the BARD opportunity in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), with P3 data expected in 1H18. Over the next 12-18 months we see four distinct clinical catalysts that hold potential for significant value creation ' and we recommend investors go long ahead of them." (2/22/2017)
  • 5. Robert W. Baird analysts commented, "Though Reata's lead asset, bardoxolone methyl, has been plagued by safety concerns in the past, we think the company has gotten its groove back. With multiple readouts over the next two years in high unmet need indications and a valuation implying more failures than successes, we think the stock is significantly undervalued and see potential for upward momentum over the next 12-18 months. Initiating at Outperform with a $43 price target." (1/24/2017)

Who are some of Reata Pharmaceuticals' key competitors?

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the folowing people:

  • J. Warren Huff, Chairman of the Board, President, Chief Executive Officer (Age 63)
  • Jason Dauglas Wilson CPA, Chief Financial Officer and Vice President, Strategy (Age 47)
  • Colin John Meyer MD, PhD, Chief Medical Officer and Vice President, Product Development (Age 38)
  • Keith Wayne Ward, Vice President, Chief Development Officer (Age 47)
  • Michael D. Wortley, Vice President, Chief Legal Officer (Age 69)
  • Dawn C. Bir, Chief Commercial Officer (Age 46)
  • William D. McClellan Jr. CPA, Director (Age 57)
  • James Edward Bass, Independent Director (Age 58)
  • R. Kent McGaughy Jr., Independent Director (Age 45)
  • Jack B. Nielsen, Independent Director (Age 53)

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Who owns Reata Pharmaceuticals stock?

Reata Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Emerald Advisers Inc. PA (3.06%), Emerald Mutual Fund Advisers Trust (2.54%), JPMorgan Chase & Co. (0.88%), Sphera Funds Management LTD. (0.79%), Alyeska Investment Group L.P. (0.35%) and Crestline Management LP (0.23%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, James Warren Huff and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.

Who sold Reata Pharmaceuticals stock? Who is selling Reata Pharmaceuticals stock?

Reata Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include A/S Novo and Abbvie Inc. View Insider Buying and Selling for Reata Pharmaceuticals.

Who bought Reata Pharmaceuticals stock? Who is buying Reata Pharmaceuticals stock?

Reata Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Emerald Mutual Fund Advisers Trust, Emerald Advisers Inc. PA, Alyeska Investment Group L.P., Crestline Management LP, Candriam Luxembourg S.C.A., Ameriprise Financial Inc. and P.A.W. Capital Corp. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include A/S Novo, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, James Warren Huff and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

How do I buy Reata Pharmaceuticals stock?

Shares of Reata Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of Reata Pharmaceuticals stock can currently be purchased for approximately $24.92.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $653.91 million and generates $49.86 million in revenue each year. The company earns $-6,220,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. Reata Pharmaceuticals employs 75 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 2801 Gateway Dr Ste 150, IRVING, TX 75063, United States. The company can be reached via phone at +1-972-8652206 or via email at [email protected]


MarketBeat Community Rating for Reata Pharmaceuticals (RETA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Reata Pharmaceuticals (NASDAQ:RETA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $54.71 (119.56% upside)

Consensus Price Target History for Reata Pharmaceuticals (NASDAQ:RETA)

Price Target History for Reata Pharmaceuticals (NASDAQ:RETA)

Analysts' Ratings History for Reata Pharmaceuticals (NASDAQ:RETA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
10/24/2017Robert W. BairdReiterated RatingBuy$47.00N/AView Rating Details
10/6/2017Jefferies Group LLCReiterated RatingBuy$44.00N/AView Rating Details
9/13/2017Leerink SwannInitiated CoverageOutperform -> Outperform$43.00MediumView Rating Details
8/23/2017Citigroup Inc.Reiterated RatingBuy$87.00 -> $78.00HighView Rating Details
7/26/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$55.00 -> $61.00HighView Rating Details
7/25/2017Stifel NicolausReiterated RatingBuy$38.00 -> $50.00HighView Rating Details
7/24/2017Piper Jaffray CompaniesBoost Price TargetBuy$53.00 -> $60.00HighView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Reata Pharmaceuticals (NASDAQ:RETA)

Earnings by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Earnings History by Quarter for Reata Pharmaceuticals (NASDAQ RETA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.39)($0.50)$12.54 million$12.60 millionViewN/AView Earnings Details
11/14/2016Q316($0.14)($0.04)$12.46 million$12.55 millionViewN/AView Earnings Details
8/11/2016Q216($0.08)($0.05)$12.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Reata Pharmaceuticals (NASDAQ:RETA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20172($0.41)($0.40)($0.41)
Q4 20172($0.51)($0.46)($0.49)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Reata Pharmaceuticals (NASDAQ:RETA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Reata Pharmaceuticals (NASDAQ RETA)

Insider Ownership Percentage: 62.40%
Institutional Ownership Percentage: 21.88%
Insider Trades by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)
Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Insider Trades by Quarter for Reata Pharmaceuticals (NASDAQ RETA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017James Edward BassDirectorBuy3,888$24.02$93,389.76View SEC Filing  
8/1/2017James Edward BassDirectorBuy8,064$31.00$249,984.00View SEC Filing  
6/14/2017A/S NovoMajor ShareholderSell61,000$25.11$1,531,710.00View SEC Filing  
6/13/2017A/S NovoMajor ShareholderSell11,389$25.47$290,077.83View SEC Filing  
6/12/2017A/S NovoMajor ShareholderSell222,503$25.71$5,720,552.13View SEC Filing  
6/7/2017A/S NovoMajor ShareholderSell89,497$28.24$2,527,395.28View SEC Filing  
6/6/2017A/S NovoMajor ShareholderSell64,170$28.09$1,802,535.30View SEC Filing  
6/5/2017A/S NovoMajor ShareholderSell23,327$28.67$668,785.09View SEC Filing  
3/28/2017Abbvie Inc.Major ShareholderSell450,000$22.50$10,125,000.00View SEC Filing  
12/30/2016Cpmg IncDirectorBuy9,392$21.72$203,994.24View SEC Filing  
12/16/2016Cpmg IncDirectorBuy164,753$22.99$3,787,671.47View SEC Filing  
12/15/2016James W Traweek JrMajor ShareholderBuy8,889$21.57$191,735.73View SEC Filing  
12/14/2016James Edward BassDirectorBuy5,000$21.76$108,800.00View SEC Filing  
8/22/2016Jack NielsenDirectorBuy1,780$17.00$30,260.00View SEC Filing  
8/18/2016R Kent Mcgaughy JrDirectorBuy308,220$17.08$5,264,397.60View SEC Filing  
8/16/2016Colin John MeyerInsiderBuy7,000$16.26$113,820.00View SEC Filing  
6/30/2016James W Traweek JrMajor ShareholderBuy164,600$19.78$3,255,788.00View SEC Filing  
6/27/2016Cpmg IncDirectorBuy73,403$19.26$1,413,741.78View SEC Filing  
6/7/2016R Kent Mcgaughy JrDirectorBuy24,220$17.57$425,545.40View SEC Filing  
6/1/2016A/S NovoMajor ShareholderBuy750,000$11.00$8,250,000.00View SEC Filing  
6/1/2016James Warren HuffInsiderBuy114,000$11.00$1,254,000.00View SEC Filing  
6/1/2016R Kent Mcgaughy JrDirectorBuy251,553$12.70$3,194,723.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Reata Pharmaceuticals (NASDAQ RETA)

Source:
DateHeadline
Reata Pharmaceuticals, Inc. (RETA) Rating Lowered to Sell at Zacks Investment ResearchReata Pharmaceuticals, Inc. (RETA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 18 at 8:18 PM
FY2017 EPS Estimates for Reata Pharmaceuticals, Inc. Cut by Leerink Swann (RETA)FY2017 EPS Estimates for Reata Pharmaceuticals, Inc. Cut by Leerink Swann (RETA)
www.americanbankingnews.com - November 17 at 8:10 PM
Jefferies Group Analysts Lower Earnings Estimates for Reata Pharmaceuticals, Inc. (RETA)Jefferies Group Analysts Lower Earnings Estimates for Reata Pharmaceuticals, Inc. (RETA)
www.americanbankingnews.com - November 17 at 8:08 PM
Insider Buying: Reata Pharmaceuticals, Inc. (RETA) Director Acquires 3,888 Shares of StockInsider Buying: Reata Pharmaceuticals, Inc. (RETA) Director Acquires 3,888 Shares of Stock
www.americanbankingnews.com - November 16 at 9:02 PM
Cowen and Company Reiterates Buy Rating for Reata Pharmaceuticals, Inc. (RETA)Cowen and Company Reiterates Buy Rating for Reata Pharmaceuticals, Inc. (RETA)
www.americanbankingnews.com - November 14 at 11:02 PM
Reata Pharmaceuticals, Inc. (RETA) Issues  Earnings Results, Misses Expectations By $0.11 EPSReata Pharmaceuticals, Inc. (RETA) Issues Earnings Results, Misses Expectations By $0.11 EPS
www.americanbankingnews.com - November 14 at 11:24 AM
Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating ResultsReata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results
finance.yahoo.com - November 14 at 7:17 AM
Is a Surprise Coming for Reata Pharmaceuticals (RETA) This Earnings Season?Is a Surprise Coming for Reata Pharmaceuticals (RETA) This Earnings Season?
finance.yahoo.com - November 9 at 12:31 PM
Reata Pharmaceuticals, Inc. (RETA) Given Consensus Recommendation of "Buy" by BrokeragesReata Pharmaceuticals, Inc. (RETA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 9 at 3:38 AM
Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week MeetingReata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting
finance.yahoo.com - November 7 at 9:34 AM
Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual MeetingReata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting
finance.yahoo.com - November 4 at 10:52 AM
$12.59 Million in Sales Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter$12.59 Million in Sales Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter
www.americanbankingnews.com - November 3 at 8:52 AM
Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : October 30, 2017Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : October 30, 2017
finance.yahoo.com - October 31 at 8:39 AM
ETFs with exposure to Reata Pharmaceuticals, Inc. : October 26, 2017ETFs with exposure to Reata Pharmaceuticals, Inc. : October 26, 2017
finance.yahoo.com - October 27 at 1:59 PM
Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RETA-US : October 27, 2017Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RETA-US : October 27, 2017
finance.yahoo.com - October 27 at 1:59 PM
Reata Pharmaceuticals (RETA) & Its Competitors Financial AnalysisReata Pharmaceuticals (RETA) & Its Competitors Financial Analysis
www.americanbankingnews.com - October 27 at 3:06 AM
Reata Pharma (RETA) Says First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of FAReata Pharma (RETA) Says First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of FA
www.streetinsider.com - October 25 at 9:48 AM
Reata Pharmaceuticals, Inc. (RETA) Rating Reiterated by Robert W. BairdReata Pharmaceuticals, Inc. (RETA) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - October 24 at 4:50 PM
Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s AtaxiaReata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia
finance.yahoo.com - October 24 at 9:14 AM
Analyzing Reata Pharmaceuticals (RETA) and Aeglea BioTherapeutics (AGLE)Analyzing Reata Pharmaceuticals (RETA) and Aeglea BioTherapeutics (AGLE)
www.americanbankingnews.com - October 22 at 6:26 PM
Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual MeetingReata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting
finance.yahoo.com - October 20 at 3:56 PM
Reata Pharmaceuticals (RETA) and Kythera Biopharmaceuticals (KYTH) Head to Head AnalysisReata Pharmaceuticals (RETA) and Kythera Biopharmaceuticals (KYTH) Head to Head Analysis
www.americanbankingnews.com - October 16 at 6:28 PM
 Analysts Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Quarterly Sales of $12.59 Million Analysts Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Quarterly Sales of $12.59 Million
www.americanbankingnews.com - October 15 at 1:32 PM
Reata Pharmaceuticals, Inc. (RETA) Receives Consensus Rating of "Buy" from AnalystsReata Pharmaceuticals, Inc. (RETA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 15 at 4:46 AM
Reviewing Reata Pharmaceuticals (RETA) & Its RivalsReviewing Reata Pharmaceuticals (RETA) & Its Rivals
www.americanbankingnews.com - October 14 at 8:14 AM
Zacks: Analysts Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Earnings of -$0.42 Per ShareZacks: Analysts Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - October 13 at 6:20 AM
Jefferies Group LLC Reiterates Buy Rating for Reata Pharmaceuticals, Inc. (RETA)Jefferies Group LLC Reiterates Buy Rating for Reata Pharmaceuticals, Inc. (RETA)
www.americanbankingnews.com - October 6 at 9:36 AM
 Brokerages Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Quarterly Sales of $12.59 Million Brokerages Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Quarterly Sales of $12.59 Million
www.americanbankingnews.com - September 26 at 3:28 AM
-$0.42 EPS Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter-$0.42 EPS Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter
www.americanbankingnews.com - September 24 at 2:28 PM
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid
finance.yahoo.com - September 22 at 4:15 PM
Reata Pharmaceuticals, Inc. (RETA) Given Average Rating of "Buy" by BrokeragesReata Pharmaceuticals, Inc. (RETA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 20 at 4:44 AM
New Strong Sell Stocks for September 15thNew Strong Sell Stocks for September 15th
www.zacks.com - September 15 at 8:10 AM
Reata Pharmaceuticals, Inc. (RETA) Expected to Earn Q3 2017 Earnings of ($0.41) Per ShareReata Pharmaceuticals, Inc. (RETA) Expected to Earn Q3 2017 Earnings of ($0.41) Per Share
www.americanbankingnews.com - September 15 at 7:20 AM
Reata Pharma (RETA) Announces FDA Orphan Drug Designation for Omaveloxolone for Treatment of Malignant MelanomaReata Pharma (RETA) Announces FDA Orphan Drug Designation for Omaveloxolone for Treatment of Malignant Melanoma
www.streetinsider.com - September 13 at 8:40 PM
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant MelanomaReata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma
finance.yahoo.com - September 13 at 8:40 PM
Leerink Swann Reiterates Outperform Rating for Reata Pharmaceuticals, Inc. (RETA)Leerink Swann Reiterates Outperform Rating for Reata Pharmaceuticals, Inc. (RETA)
www.americanbankingnews.com - September 13 at 9:52 AM
Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RETA-US : September 1, 2017Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RETA-US : September 1, 2017
finance.yahoo.com - September 2 at 8:02 AM
Robert W. Baird Reaffirms Buy Rating for Reata Pharmaceuticals, Inc. (RETA)Robert W. Baird Reaffirms Buy Rating for Reata Pharmaceuticals, Inc. (RETA)
www.americanbankingnews.com - September 1 at 8:56 PM
ETFs with exposure to Reata Pharmaceuticals, Inc. : September 1, 2017ETFs with exposure to Reata Pharmaceuticals, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 7:56 AM
Equities Analysts Set Expectations for Reata Pharmaceuticals, Inc.s Q3 2017 Earnings (RETA)Equities Analysts Set Expectations for Reata Pharmaceuticals, Inc.'s Q3 2017 Earnings (RETA)
www.americanbankingnews.com - September 1 at 6:56 AM
Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in EuropeFeatured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe
finance.yahoo.com - August 31 at 9:21 AM
Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in EuropeFeatured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe
finance.yahoo.com - August 31 at 9:21 AM
Reata Pharmaceuticals, Inc. (RETA) Receives New Coverage from Analysts at Jefferies Group LLCReata Pharmaceuticals, Inc. (RETA) Receives New Coverage from Analysts at Jefferies Group LLC
www.americanbankingnews.com - August 30 at 10:28 AM
Reata Pharmaceuticals, Inc. :RETA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017Reata Pharmaceuticals, Inc. :RETA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 8:47 AM
Reata Pharmaceuticals, Inc. (RETA) Receives Average Rating of "Buy" from BrokeragesReata Pharmaceuticals, Inc. (RETA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 26 at 4:34 AM
Reata Pharmaceuticals, Inc. (RETA) Receives Buy Rating from Citigroup Inc.Reata Pharmaceuticals, Inc. (RETA) Receives Buy Rating from Citigroup Inc.
www.americanbankingnews.com - August 23 at 2:56 PM
$12.63 Million in Sales Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter$12.63 Million in Sales Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter
www.americanbankingnews.com - August 20 at 11:16 AM
-$0.34 EPS Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter-$0.34 EPS Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter
www.americanbankingnews.com - August 18 at 8:12 AM
Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : August 15, 2017Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : August 15, 2017
finance.yahoo.com - August 16 at 7:16 AM
FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s AtaxiaFDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia
finance.yahoo.com - August 15 at 6:40 AM

Social Media

Financials

Chart

Reata Pharmaceuticals (NASDAQ RETA) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.